Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Title: Affymetrix SNP array data for Primary Effusion Lymphoma samples      
keywords:
Variation
ID:
PRJNA135755
description:
Primary Effusion Lymphoma (PEL) is a Diffuse-Large B-cell Lymphoma (DLBCL) with poor prognosis. 100% of PEL carry the genome of Kaposi's Sarcoma-associated herpesvirus (KSHV) and approximately half are co-infected with Epstein-Barr virus (EBV). We profiled genomic aberrations in PEL using the Affymetrix 6.0 SNP array. This identified for the first time individual genes that are altered in PEL. 10/13 (76%) samples were deleted for both the fragile site tumor suppressors WWOX and FHIT. Alterations were also observed in: DERL1, ETV1, RASA4, TPK1, TRIM56 and VPS41 genes, which are yet to be characterized for their roles in cancer. Co-infection with EBV was associated with significantly fewer gross genomic aberrations. PEL could be segregated into EBV positive and EBV negative clusters on the basis of host chromosome alterations. The genomic signature of PEL cells in culture was analogous to those explanted from xenograft tumors. This suggests a model in which both host and virus contribute to the PEL phenotype. Overall design: 17 samples (no replicates) were analyzed using Partek Genomic Suite software
accesstypes:
download
landingpage: http://www.ncbi.nlm.nih.gov/bioproject/PRJNA135755
authentication:
none
authorization:
none
ID:
pmid:21685375
dateReleased:
06-23-2011
name:
Homo sapiens
ncbiID:
ncbitax:9606
abbreviation:
NCBI
homePage: http://www.ncbi.nlm.nih.gov
ID:
SCR:006472
name:
National Center for Biotechnology Information
homePage: http://www.ncbi.nlm.nih.gov/bioproject
ID:
SCR:004801
name:
NCBI BioProject
  • P01 CA019014/CA/NCI NIH HHS/United States

  • R01 CA163217/CA/NCI NIH HHS/United States

  • DE018304/DE/NIDCR NIH HHS/United States

  • CA096500/CA/NCI NIH HHS/United States

  • DE018281/DE/NIDCR NIH HHS/United States

  • CA121947/CA/NCI NIH HHS/United States

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on GitHub.